Navigation Links
Kensey Nash and Arthrex Announce European Distribution Agreement for the Cartilage Repair Device
Date:11/9/2010

EXTON, Pa., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY), a regenerative medicine company, and Arthrex, Inc., a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons, jointly announced an agreement for the European distribution of Kensey Nash's unique Cartilage Repair Device (CRD).

Kensey Nash's CRD technology consists of a biphasic bioresorbable scaffold intended to be implanted at the site of a focal articular cartilage lesion or osteochondral defect in the knee. The product is CE Marked and indicated to support the regeneration of hyaline cartilage and subchondral bone by promoting the correct cellular morphology and structural organization during the healing process. Currently, the CRD is the subject of an FDA approved pilot clinical trial and not yet approved for sale in the US.

Pursuant to the agreement, Kensey Nash will exclusively supply the CRD to Arthrex for European marketing and distribution in accordance with the Company's CE Mark approval.  Other terms of the agreement were not disclosed.

"This partnership represents an important milestone as we continue Kensey Nash's mission as a developer of innovative regenerative medicine products," commented Joseph W. Kaufmann, President and CEO of Kensey Nash. "We look forward to building upon our excellent relationship with our strategic partner Arthrex, a highly respected global leader in the sports medicine industry," he concluded.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology.  The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials.  The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including, the cardiology, orthopaedic, sports medicine, spine, endovascular and general surgery markets.

About Arthrex, Inc.  Arthrex, headquartered in Naples, Florida, is a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons. Over 5,000 products for arthroscopic and minimally invasive orthopaedic surgical procedures have been developed by Arthrex and are currently marketed worldwide. For more information, visit www.arthrex.com.

Kensey Nash Cautionary Note for Forward-Looking Statements.  This press release contains forward-looking statements that reflect the current expectations of Kensey Nash Corporation (the "Company") about its prospects and opportunities.  The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "should," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements.  The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, Arthrex's success in selling the Company's cartilage repair product pursuant to the agreement(or otherwise), the Company's success in its research and development efforts in its cartilage repair technologies programs, the success of U.S. trials with respect to the Company's cartilage repair products and completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of its products, competition from other technologies, the Company's success in distributing its products into the marketplace, as well as tax and other risks associated with healthcare reform, economic conditions and foreign currency fluctuations. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosures under "Risk Factors" in those filings.  Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kensey Nash Announces IDE Submission for Cartilage Repair Device
2. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
4. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
5. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
6. Kensey Nash Announces $30 Million Share Buyback
7. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
8. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
9. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
10. Kensey Nash to Present at the Ninth Annual JMP Securities Research Conference
11. KENSEY NASH Receives FDA 510(k) Clearance for ECM Product, Meso BioMatrix Surgical Mesh
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):